Posts

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by